CORRIGENDUM to “Dual-targeting strategy using trastuzumab and lapatinib in a patient with HER2 gene amplification in recurrent metachronous metastatic gallbladder carcinoma”

Ye M, Lv J, Xu G, et al. Dual-targeting strategy using trastuzumab and lapatinib in a patient with HER2 gene amplification in recurrent metachronous metastatic gallbladder carcinoma. Journal of International Medical Research 2019; 47(6): 2768–2777. doi: 10.1177/0300060519847796

The funding statement of the above article was incorrect. The correct funding statement is given below.

This study was supported by Key Disciplines Foundation of Digestive System Oncology (Grants No. zd201114), rather than National Natural Science Foundation of China (Grants No. 81374014 and 81472210) or Zhejiang Provincial Medical and Healthy Science and Technology Projects (Grant No. 2013KYA228).